Literature DB >> 11474910

The role of serotonin in the pathophysiology of irritable bowel syndrome.

M D Crowell.   

Abstract

Coordinated activities of the central, autonomic, and enteric nervous systems modulate intestinal motor, sensory, and secretory activities that may contribute to the triad of dysfunction (altered motility, altered sensation, and psychosocial distress) observed in patients with irritable bowel syndrome (IBS). Autonomic modulation of gastrointestinal (GI) function occurs via the actions of neurotransmitters and neuromodulators such as serotonin (5-hydroxytryptamine, or 5-HT), norepinephrine, and dopamine. Of those modulators, serotonin has received the most attention with respect to disorders of GI function. Serotonin exerts its effects via neurocrine, paracrine, and endocrine pathways. Recent studies have demonstrated that serotonin, acting primarily through 5-HT3 and 5-HT4 receptors, is intricately involved in initiating the peristaltic reflex and facilitating intraluminal secretions. Serotonin receptors mediate reflex control of GI motility and secretion and may influence the perception of bowel function and pain under some circumstances. GI motor activity and sensory dysfunction in patients with IBS may be a result of alterations in serotonin levels or associated 5-HT receptors. Serotonin agonists and antagonists such as tegaserod, a 5-HT4 agonist, may offer new treatments that normalize GI motor and sensory functions in patients with disorders of GI function.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11474910

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  23 in total

1.  Activation of submucosal 5-HT(3) receptors elicits a somatostatin-dependent inhibition of ion secretion in rat colon.

Authors:  N Yang; S M Liu; L F Zheng; T Ji; Y Li; X L Mi; H Xue; W Ren; J D Xu; X H Zhang; L S Li; Y Zhang; J X Zhu
Journal:  Br J Pharmacol       Date:  2010-03-05       Impact factor: 8.739

Review 2.  Need for a comprehensive medical approach to the neuro-immuno-gastroenterology of irritable bowel syndrome.

Authors:  Pejman Katiraei; Gilberto Bultron
Journal:  World J Gastroenterol       Date:  2011-06-21       Impact factor: 5.742

Review 3.  Symptom overlap and comorbidity of irritable bowel syndrome with other conditions.

Authors:  Christine L Frissora; Kenneth L Koch
Journal:  Curr Gastroenterol Rep       Date:  2005-08

Review 4.  The role of gender and biological sex in irritable bowel syndrome.

Authors:  Christine L Frissora; Kenneth L Koch
Journal:  Curr Gastroenterol Rep       Date:  2005-08

Review 5.  New treatments for irritable bowel syndrome in women.

Authors:  Mopelola A Adeyemo; Lin Chang
Journal:  Womens Health (Lond)       Date:  2008-11

Review 6.  Physiological genomics of antidepressant targets: keeping the periphery in mind.

Authors:  R D Blakely
Journal:  J Neurosci       Date:  2001-11-01       Impact factor: 6.167

Review 7.  5-HT3 receptors.

Authors:  A J Thompson; S C R Lummis
Journal:  Curr Pharm Des       Date:  2006       Impact factor: 3.116

Review 8.  Review of the treatment options for chronic constipation.

Authors:  John F Johanson
Journal:  MedGenMed       Date:  2007-05-02

9.  Prucalopride: the evidence for its use in the treatment of chronic constipation.

Authors:  Georges Coremans
Journal:  Core Evid       Date:  2008-06

Review 10.  Role of serotonin in the pathophysiology of the irritable bowel syndrome.

Authors:  Michael D Crowell
Journal:  Br J Pharmacol       Date:  2004-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.